691872-15-8

Basic information

• Product Name: 5-Bromo-2-nitro-3-Pyridinol
• Synonyms: 5-Bromo-2-nitro-3-Pyridinol;5-BroMo-2-nitropyridin-3-ol;5-BroMo-3-hydroxy-2-nitropyridine;3-Pyridinol, 5-bromo-2-nitro-
• CAS NO: 691872-15-8
• Molecular Formula: C₅H₃BrN₂O₃
• Molecular Weight: 218.99292
• Mol File: 691872-15-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 393.4±37.0 °C(Predicted)
• Appearance: /
• Density: 2.006±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.63±0.10(Predicted)
• CAS DataBase Reference: 5-Bromo-2-nitro-3-Pyridinol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-nitro-3-Pyridinol(691872-15-8)
• EPA Substance Registry System: 5-Bromo-2-nitro-3-Pyridinol(691872-15-8)

Safety Data

• Hazardous Substances Data: 691872-15-8(Hazardous Substances Data)

Usage

Uses

5-Bromo-3-hydroxy-2-nitropyridine was used to design potent and selective inhibitors to overcome clinical anaplastic Lymphoma kinase mutations resistant to Crizotinib (C785000), a potential antitumor agent.

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 

Downstream Products

• 756503-69-2 (±)-5-bromo-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)pyridin-2-amine 

Relevant articles and documents

Macrocyclic JAK2 inhibitor and application thereof

The invention relates to a macrocyclic JAK2 inhibitor and an application thereof. Specifically, the invention relates to a compound shown as a formula I and an application of the compound in treatingJAK2-mediated related diseases and preparing medicines for treating the JAK2-mediated related diseases.

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors

Janus kinases (JAKs) including JAK1, JAK2, JAK3, and TYK2 are members of a family of intracellular nonreceptor tyrosine kinases, which have been demonstrated to be critical in the cell signaling pathway and involved in inflammatory diseases and cancer. V617F mutation in JAK2 has been implicated in polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF). Here, we described the design, synthesis, and biological evaluation of a series of 2-aminopyridine derivatives. The results of enzymatic activity assays supported compound 16m-(R) as a potential and selective JAK2 inhibitor, which exhibited high inhibitory activity with an IC50 of 3 nM against JAK2, and 85- and 76-fold selectivity over JAK1 and JAK3, respectively. Structure-activity relationships (SAR) and mechanistic analysis demonstrated that 16m-(R) might be a promising selective JAK2 inhibitor for further study.

Design and Synthesis of a Series of Novel Macrocycle Janus Kinase 2 Inhibitors

Macrocycle has attracted the attention of many researchers in the field of medicinal chemistry due to its unique advantages and good prospects, but the difficulties in drug design and synthesis of macrocycle limit its applications. In this study, a series of macrocyclic derivatives designed from anaplastic lymphoma kinase (ALK) inhibitor lorlatinib were synthesized as Janus kinase 2 (JAK2) selective inhibitors. Among them, 17f had the best inhibitory activity (IC50 = 0.177 μmol·L–1) and selectivity for JAK2 over JAK1 and JAK3, which indicated that design of the macrocyclic derivatives might be a feasible strategy for the discovery of novel selective JAK2 inhibitors.